Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
DKC1
REST API REST API
Homo sapiens
DKC1 is differentially expressed in 344 experiments: 145 organism parts: bone marrow, liver, ... (143 more);, 267 disease states: normal, colon carcinoma, ... (265 more);, 106 cell types 424 cell lines 41 compound treatments and 85 other conditions.
Synonyms dyskerin, XAP101, NAP57, DKC, NOLA4
Orthologs Dkc1 (Mus musculus)   CBF5 (Saccharomyces cerevisiae)   DKC1 (Gallus gallus)   dkc1 (Danio rerio)   A7YWH5_BOVIN (Bos taurus)   A8DRX9_CIOIN (Ciona intestinalis)   Nop60B (Drosophila melanogaster)   B0BMM6_XENTR (Xenopus laevis)   ENSCAFG00000009311 (Canis familiaris)   XM_549382.2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term rRNA processing, telomere maintenance, pseudouridine synthase activity, isomerase activity, protein binding, Cajal body, cell proliferation, RNA processing, pseudouridine synthesis, nucleus, nucleoplasm, RNA binding, nucleolus, telomere maintenance via telomerase, telomerase activity, telomerase holoenzyme complex
InterPro Term PUA, Dyskerin-like, Pseudouridine_synthase-related, PsdUridine_synth, Uncharacterised_CHP00451
UniProt Accession A8MUT5, C9IYT0, O60832
Gene-Disease Assocation HOYERAAL-HREIDARSSON SYNDROME; HHS, DYSKERATOSIS CONGENITA, X-LINKED; DKCX
Search EB-eye ENSG00000130826
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-6573, E-GEOD-1577, E-MEXP-433, E-GEOD-3526, E-MTAB-62, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (38 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-3529, E-GEOD-19639, E-GEOD-5823
HCC38
2
E-MTAB-62, E-MTAB-37
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
MDA468
2
E-MEXP-440, E-MTAB-62
MOLT4
2
E-MTAB-37, E-MTAB-62
SW480
2
E-MEXP-1014, E-MTAB-37
418 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, E-GEOD-21750, ... (50 experiments)

Factor Value U/D Experiments
macrophage
2
E-GEOD-22373, E-GEOD-3982
721 B lymphoblast
1
2
E-AFMX-5, E-TABM-145
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
human embryonic stem cell
1
2
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
multipotent adult progenitor cell
1
E-MEXP-466
100 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, E-MTAB-62, ... (78 experiments)

Factor Value U/D Experiments
colon carcinoma
4
E-MTAB-62, E-GEOD-3726, E-MTAB-37, E-MTAB-57
lung adenocarcinoma
4
E-MTAB-37, E-GEOD-2514, E-MEXP-231, E-MTAB-62
Huntington's disease
3
E-AFMX-6, E-GEOD-3790, E-GEOD-1751
chronic myelogenous leukemia
3
E-MTAB-62, E-GEOD-5550, E-MTAB-37
prostate carcinoma
3
E-MEXP-1327, E-MTAB-62, E-GEOD-96
T-cell acute lymphoblastic leukemia
2
E-MTAB-37, E-GEOD-1577
261 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (30 experiments)

Factor Value U/D Experiments
5-aza-2'-deoxycytidine
3
2
E-GEOD-5230, E-MEXP-1269
dimethyl sulfoxide
2
E-GEOD-5824, E-GEOD-6932
glutamine
2
E-MEXP-1335, E-MEXP-941
lipopolysaccharide
2
E-GEOD-3720, E-TABM-868
control
1
2
E-GEOD-5339, E-GEOD-3284, E-GEOD-4006
chloroguine
1
E-GEOD-5418
35 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
50
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-22513, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-19018, E-GEOD-20033, E-MEXP-2359, ... (11 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-MTAB-69, E-TABM-147, E-GEOD-3013 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-GEOD-22056, E-GEOD-3494, E-GEOD-17476, E-GEOD-22593, E-TABM-321, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-20540, E-GEOD-22278, E-TABM-440, E-GEOD-837, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-20559, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (31 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, E-GEOD-17400, ... (7 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-MEXP-2177

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (6 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-MEXP-548, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-7307

Stimulation
studied in E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-1561, E-GEOD-4922, E-TABM-147 ... (5 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.294 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM